GlassScriptPhysician profile
Charles S Henry
NPI 1245201995
$6,126.50
in general payments reported to CMS, 2019-2025
29 companies · $960 in 2025
The $960 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $747 · 2021: $638 · 2022: $854 · 2023: $749 · 2024: $1,279 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Education: $57.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.18 |
| Education | $57.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $754.89 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $693.83 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $487.53 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $478.36 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $458.51 | 2019-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $445.63 | 2023-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $381.60 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $336.62 | 2020-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $250.17 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $230.17 | 2019-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $208.25 | 2022-2025 | |
| Horizon Therapeutics Plc | $198.80 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $188.99 | 2023-2025 | |
| Nxstage Medical, INC. | $118.84 | 2022 | |
| Novo Nordisk INC | $114.20 | 2024-2025 | Rybelsus, Ozempic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $113.73 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $92.81 | 2023-2025 | Lupkynis |
| Genzyme Corporation | $87.09 | 2019-2021 | |
| Cormedix INC. | $87.01 | 2024-2025 | Defencath, Defencath |
| Mallinckrodt Enterprises LLC | $81.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $65.70 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $63.43 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $58.58 | 2019-2022 | |
| Amarin Pharma, INC. | $41.50 | 2020 | |
| Glaxosmithkline, LLC. | $32.35 | 2021-2023 | Benlysta |
| Daiichi Sankyo INC. | $20.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.